Ernexa Therapeutics Inc.
ERNA
$0.29
$0.001.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -94.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -94.12% |
| Cost of Revenue | -- | -- | -- | -- | -100.00% |
| Gross Profit | -- | -- | -- | -- | 102.04% |
| SG&A Expenses | -7.92% | -71.67% | -64.96% | -67.07% | -66.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.39% | -53.89% | -49.76% | -53.21% | -53.34% |
| Operating Income | 22.36% | 48.03% | 49.28% | 52.83% | 53.22% |
| Income Before Tax | 72.79% | 95.36% | 43.25% | -23.35% | 6.64% |
| Income Tax Expenses | -663.64% | -50.00% | 0.00% | 100.00% | 375.00% |
| Earnings from Continuing Operations | 73.92% | 95.34% | 43.23% | -23.39% | 6.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.92% | 95.34% | 43.23% | -23.39% | 6.40% |
| EBIT | 22.36% | 48.03% | 49.28% | 52.83% | 53.22% |
| EBITDA | 22.29% | 47.97% | 49.17% | 52.82% | 53.37% |
| EPS Basic | 91.89% | 99.80% | 96.04% | 87.49% | 86.79% |
| Normalized Basic EPS | 92.70% | 98.49% | 96.09% | 87.49% | 84.49% |
| EPS Diluted | 91.89% | 99.80% | 96.04% | 87.49% | 86.79% |
| Normalized Diluted EPS | 92.70% | 98.49% | 96.09% | 87.49% | 84.49% |
| Average Basic Shares Outstanding | 222.92% | 2,178.67% | 1,334.63% | 886.25% | 608.51% |
| Average Diluted Shares Outstanding | 222.92% | 2,178.67% | 1,334.63% | 886.25% | 608.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |